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Introduction    
INTRODUCTION 
  Heart Failure (HF) is a major public health problem that is 
associated with markedly diminished survival. Heart Failure (HF) has 
classically been considered to be a Clinical Syndrome associated with 
Cardiac dilation and impaired cardiac contractility (1). 
  Several studies have reported that a high proportion of patients 
with HF are found to have a normal left Ventricular Function and an 
Ejection Fraction(EF) of more than 50%. This has variously been 
labeled as Diastolic Heart Failure, “Heart Failure with Preserved 
Ejection Fraction”(HFPEF)
(2) 
or“ Heart Failure with normal Ejection 
Fraction”(HFnlEF)
(6)
 and is attributed to abnormalities of Diastolic 
function although the exact mechanism is debated
(3,4)
. The 
epidemiology, aetiology and pathophysiology of this condition are 
reviewed recently. 
  Prior data suggest that patients who have HF with Preserved 
Ejection Fraction tend to be older, to be female and to have a history of 
Hypertension (HT)
(2,5)
. 
  The EF threshold (or “cutoff”) value used to differentiate the 
Heart Failure patients as Reduced EF and Normal or Preserved EF 
ranged from 40% to 50% in a variety of studies. What is the ideal 
threshold value? Data indicate that patients with an EF between 40% 
and 50% behave more like patients with EF 40%. The major conclusions 
of Smith et al.
(8)
 would not be changed if the EF cutoff was >50% 
instead of >40%. Therefore, it is reasonable to conclude that the ideal 
cutoff to differentiate Reduced EF from Preserved EF is 50%. 
  We performed a study to analyze the clinical and echo profile in 
HF with Preserved Ejection Fraction among patients admitted for HF in 
our Hospital over a period of one year to assess the relative proportions 
of Normal Versus Reduced EF. 
  
 
 
 
 
 
 
 
 
 
 
 
Aims & Objectives          
AIM AND OBJECTIVES 
 
1. To study about the clinical Features of patients with Heart 
Failure with Preserved Ejection Fraction. 
2. To study about the Echocardiographic features of Heart Failure 
with Preserved Ejection Fraction. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature            
REVIEW OF LITERATURE 
3.1 DEFINITIONS : 
1. Heart Failure: A pathophysiological state in which abnormality of 
cardiac function is responsible for the failure of the heart to pump blood 
at a rate commensurate with requirements of the metabolizing tissues
(1)
. 
2. Ejection fraction: By definition, the volume of blood within a 
ventricle immediately before a contraction is known as the end-diastolic 
volume. Similarly, the volume of blood left in a ventricle at the end of 
contraction is end-systolic volume. The difference between end-diastolic 
and end-systolic volumes is the stroke volume, the volume of blood 
ejected with each beat. Ejection fraction (EF) is the fraction of the end-
diastolic volume that is ejected with each beat; that is, it is stroke 
volume (SV) divided by end-diastolic volume (EDV): 
SV EDV ESV
EF
EDV EDV
−
= =  
1.HFNEF: Symptoms and signs of Heart Failure with Left Ventricular 
Ejection Fraction ≥50% by Echocardiography
(4)
. 
 
3.2 EPIDEMIOLOGY: 
 Epidemiological studies have defined the prevalence of HF with 
Preserved EF in various HF populations and have documented a 
prevalence of 50% to 55%. 
 The prevalence of HFnlEF among patients with HF varies 
dramatically with Age and Gender. Much more common in women than 
in men at any age in contrast to HF with Depressed EF which is 
common in men than in women. Most contemporary studies have been 
suggested that Mortality of HF with Normal Ejection Fraction is similar 
to that of HF with reduced Ejection Fraction. Difference in survival 
between two categories of HF is minimal. Although survival has 
improved over time for patients with HF with a reduced EF but it has 
not changed for patients with HFnlEF 
(1)
.  
 
3.3 CLINICAL FEATURES: 
 HFnlEF were shown to have similar Pathophysiological 
characteristics compared with patients with a Reduced EF. 
 Framingham criteria for diagnosis of Heart Failure: 
 
 
TABLE NO- 1    
Clinical Features of Heart Failure with  
Normal Ejection Fraction
(1) 
 
Parameter Features 
Framingham criteria for diagnosis of heart failure[*] 
 Major criteria 
  
  
  
  
  
  
  
  
Paroxysmal nocturnal dyspnea or orthopnea 
Jugular venous distention (or CVP > 16 mm Hg) 
Rales or acute pulmonary edema 
Cardiomegaly 
Hepatojugular reflex 
Response to diuretic (weight loss >4.5 kg in 5 
days) 
Minor criteria  
  
  
  
  
  
  
  
  
Ankle edema 
Nocturnal cough 
Exertional dyspnea 
Pleural effusion 
Vital capacity < two thirds of normal 
Hepatomegaly 
Tachycardia (>120 bpm) 
Demographic 
features 
Elderly; female > male 
Underlying CV 
disease 
Hypertension, coronary disease, diabetes, atrial 
fibrillation 
Comorbidities Obesity, renal dysfunction 
Doppler echocardiography results 
LV size Normal to ↓ (small subset with↑) 
LV mass LVH common but frequently absent; ↑ relative 
wall thickness (> 0.45) 
Left atrium Enlarged 
Diastolic Grade I-IV (∞ diastolic dysfunction severity, BP, 
Parameter Features 
dysfunction volume status) 
Other features PH, wall motion abnormality, RV enlargement 
Pertinent negatives Rule out valve disease, pericardial disease, ASD 
BNP or NT-proBNP ↑ but HFnlEF < HFrEF 
Exercise testing 
  
  
  
↓ VO2 peak 
Exaggerated hypertensive response in many 
Chronotropic incompetence in subset 
Chest radiogram Similar to HFrEF, cardiomegaly, pulmonary 
venous hypertension, edema, pleural effusion 
Electrocardiogram Variable 
*  Two major or one major and two minor criteria 
 
None of the clinical features can be used to distinguish patients 
with HFnlEF reliably from those with HF with reduced EF. Thus 
assessment of EF with cardiac imaging is needed to distinguish HFnlEF 
with a reduced EF. 
 
3.4.AETIOLOGY: 
1. Aging: Structural cardiac changes with aging (e.g., increased 
cardiomyocyte size, increased apoptosis with decreased myocyte 
number, altered growth factor regulation, focal collagen deposition) 
and functional changes at the cellular level involving blunted beta-
adrenergic responsiveness, excitation-contraction coupling, and 
altered calcium-handling proteins may contribute to diastolic 
dysfunction with normal aging. 
2. Female Gender: The female predominance in HFnlEF are not 
entirely clear, but women have higher vascular and LV systolic and 
diastolic stiffness than men, and vascular and ventricular stiffness 
increases more dramatically with age in women
 (9)
. 
3. Hypertension (HT): Chronically increased blood pressure is an 
important stimulus for cardiac structural remodeling and functional 
changes. The resultant hypertensive heart disease is characterized by 
LV hypertrophy (LVH), increasing vascular and ventricular systolic 
stiffness, impaired relaxation, and increased diastolic stiffness, all 
factors linked to the pathogenesis of HFnlEF
(10)
. 
4. Coronary Artery Disease (CAD): Acute and chronic Ischemia is 
known to cause Diastolic dysfunction and is the leading cause of HF 
in both Reduced and Normal EF (5). 
5. Atrial Fibrillation: May cause decompensated HF in patients with 
diastolic dysfunction and diastolic dysfunction (in the absence of HF) 
is also a risk factor for atrial fibrillation. Thus, diastolic dysfunction, 
atrial fibrillation, and HFnlEF are common and related conditions 
that probably share common pathogenic mechanisms in the elderly. 
6. Obesity: Increased adiposity imposes an adverse hemodynamic load 
on the heart and also a source of a large number of biologically 
active peptide and nonpeptide mediators, many linked to chronic 
inflammation by various pathways. Increased body mass index 
(BMI) is a risk factor for hypertension, diabetes mellitus, coronary 
artery disease, and atrial fibrillation, all of which are associated with 
HFnlEF. 
7. Diabetes Mellitus: The morphological changes in the diabetic heart 
include myocyte hypertrophy, increased extracellular matrix 
(fibrosis), and intramyocardial microangiopathy. Functional changes, 
which may represent a continuum, include endothelial-dependent and 
endothelial-independent microvascular dysfunction, impaired 
relaxation, and increased passive diastolic stiffness and contractile 
dysfunction. Mechanisms contributing to structural and functional 
coronary vascular and myocardial changes are diverse and include 
metabolic disturbances, activation of proinflammatory and 
profibrotic mediators, cardiac autonomic neuropathy, and increases 
in advanced glycation end-products (AGE), which promote increased 
collagen accumulation and increased collagen stiffness. AGE 
accumulation may also play a role in age-related cardiovascular 
stiffening. 
8. Renal Failure: Bilateral renal artery stenosis with rapid-onset or 
flash pulmonary edema is a well-recognized cause of HFnlEF.  
9. Cardiomyopathy-HOCM (Hypertrophic Obstructive 
Cardiomyopathy), Infiltrative Cardiomyopathies(Amyloidosis), 
Idiopathic Restrictive Cardiomyopathy. 
10. Constrictive Pericarditis. 
11. Radiation Heart Disease. 
12. Anemia, Thyrotoxicosis(14), Obstructive sleep Apnea(13). 
13. Excessive use of Salty foods, Non-steriodal Anti-inflammatory 
drugs, Thiazolidinediones etc.
(13)
 
 
3.5 PATHOPHYSIOLOGY: 
 Understanding Pathophysiological mechanism in HFnlEF 
mandates a clear understanding of LV diastolic and systolic function. 
 
3.51 CARDIAC CYCLE: 
The period from the beginning of one heart beat to the beginning 
of the next is called the cardiac cycle. Each cycle is initiated by 
spontaneous generation of an action potential in the sinus node. The 
action potential travels rapidly through both atria and then through the 
A-V bundle into the ventricles. However, because of a special 
arrangement of the conducting system from the atria into ventricles, 
there is a delay of more than 1/10 second between passage of the cardiac 
impulse from the atria into the ventricles. This allows the atria to 
contract ahead of the ventricles, thereby, pumping blood into the 
ventricles prior to the very strong ventricular contraction. Thus, the atria 
act as primer pumps for the ventricles, and the ventricles then provide 
the major source of power for moving blood through the vascular 
system
(17)
. 
The cardiac cycle consists of a period of relaxation called 
diastole, during which the heart fills with blood followed by a period of 
contraction called systole. 
Blood normally flows continually from the great veins into the 
atria; approximately 75 percent of blood flows directly through the atria 
into the ventricles even before the atria contract, then atrial contraction 
usually causes an additional 25 percent filling of the ventricles. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Therefore, the atria simply function as primer pumps that increase 
the ventricular pumping effectiveness as much as 25 percent. Yet, the 
heart can continue to operate quite satisfactorily under normal resting 
conditions even without this extra 25 percent effectiveness because it 
normally has the capability of pumping 300 to 400 percent more blood 
than is required by the body anyway. Therefore, when the atria fail to 
function, the difference is unlikely to be noticed unless a person 
exercises; then acute signs of heart failure occasionally develop, 
especially shortness of breath. 
Function of the Ventricles: 
During ventricular systole, large amounts of blood accumulate in 
the atria because of the closed A-V valves. Therefore, just as soon as 
systole is over and the ventricular pressures fall again to their low 
diastolic values, the high pressures in the atria immediately push the A-
V valves open and allow the blood to flow rapidly into the ventricles. 
 
3.511 PHYSIOLOGY OF SYSTOLE: 
Period of Isovolumic (isometric) contraction:  
Immediately after ventricular contraction begins, the ventricular 
pressure abruptly rises causing the A-V valves to close. Then an 
additional 0.02 to 0.03 second is required for the ventricle to build up 
sufficient pressure to push the semilunar (aortic and pulmonary) valves 
open against the pressures in the aorta and pulmonary artery. Therefore, 
during this period of time, contraction is occuring in the ventricles, but 
there is no emptying. This period is called the period of isovolumic or 
isometric contraction, meaning by these terms that tension is increasing 
in the muscle, but no shortening of the muscle fibres is occuring. 
 
 
 
 
Period of ejection: 
When the left ventricular pressure rises slightly above 80 mm Hg 
(and the right ventricular pressure slightly above 80 mm Hg), the 
ventricular pressure now push the semilunar valves open, Immediately , 
blood begins to pour out of the ventricle, with about 70 per cent of the 
emptying occuring during the first third of the period of ejection and the 
remaining 30 percent during the next two thirds. Therefore, the first 
third is called the period of rapid ejection and the last two thirds the 
period of slow ejection. For a very peculiar reason, the ventricular 
pressure falls to value slightly below that in the aorta during the period 
of slow ejection, despite the fact that some blood is still leaving the left 
ventricle. The reason is that the blood flowing out of the ventricle has 
built up momentum. As this momentum decrease during the latter part 
of systole, the kinetic energy of the momentum is converted into 
pressure in the aorta, which makes the arterial pressure slightly greater 
than the pressure inside the ventricles. 
 
Period of Isovolumic (Isometric) Relaxation: 
At the end of systole, ventricular relaxation begins suddenly, 
allowing the Intraventricular pressure to fall rapidly. The elevated 
pressures the distended large arteries immediately push blood back 
toward the ventricles, which snaps the aortic and pulmonary valves 
closed. For another 0.03 to 0.06 second, the ventricular muscle 
continues to relax, even though the ventricular volume does not change, 
giving rise to the period of Isovolumic or isometric relaxation. During 
this period, the Intraventricular pressure fall rapidly back to their low 
diastolic levels. Then the A-V valves open to begin a new cycle of 
ventricular pumping. 
 
End- Diastolic volume, End- systolic and stroke volume output: 
During diastole, filling of the ventricles normally increase the 
volume of each ventricle to about 100 to 120 milliliters (ml). This 
volume is known as the end- diastolic volume. Then as the ventricles 
empty during systole, the volume decrease by about 70 ml, which is 
called the stroke volume output. The remaining volume in each ventricle, 
about 40 to 50 ml, is called the end-systolic volume. The fraction of the 
end- diastolic volume that is ejected is called the ejection fraction- 
usually equal to about 60 percent. The cardiac cycle which is divided into 
two periods, viz., systole and diastole, can be further subdivided into 
phases of cardiac-activity as described. 
The first phase of ventricular systole is Isovolumic (isovolumetric 
or isochoric) contraction. This phase begins with the first detectable rise 
in left ventricular pressure, it is associated with the initial, mitral 
component (MC) of the first heart sound. The end of the Isovolumic 
contraction phase and the beginning of the succeeding rapid ventricular 
ejection phase are indicated by the opening of the aortic valve (AO), a 
rise in aortic pressure, a decrease in ventricular volume. The onset and 
termination of the next phase of reduced ventricular ejection are less well 
defined. This normally occurs prior to the peak systolic pressure in the 
left ventricle and aorta. The phase of reduced ejection lasts until the end 
of actual ejection and the beginning of diastole. The very brief initial 
phase of diastole is referred to as protodiastole and represents the time 
required for the reversal of flow in the aorta and for closure of the aortic 
valve. The beginning of the next phase of isovolumic relaxation of the 
left ventricle is signified by the closure of the aortic valve, as indicated 
by the second heart sound. Isovolumic relaxation lasts until the left 
ventricular pressure falls below the left atrial pressure and blood begins 
to flow from the atrium into the ventricle. Both isovolumic relaxation and 
the following phase of rapid ventricular filling are produced by elastic 
record and active relaxation of the ventricular myocardium. 
The end of the isovolumic relaxation phase and the beginning of 
the rapid ventricular filling are indicated by an increase in the ventricular 
volume curve, which coincides with the opening of the mitral valve. 
 
 
3.512 PHYSIOLOGY OF DIASTOLE: 
We operationally define diastole as the phase of the cardiac cycle 
that starts with the onset of isovolumic relaxation and ends with the 
cessation of inflow, because factors that determine left ventricular filling 
are operative at this time period. It is thus clear that both the active and 
passive properties of the ventricle must be included in our discussion of 
the determinants of filling, because both contribute to the phasic 
atrioventricular pressure gradient. Conceptually, it has been suggested 
that systole defines one entire contraction - relaxation cycle, thus 
restricting diastole to that phase of cardiac cycle separating two 
contraction- relaxation cycles, i.e., diastasis and atrial systole. 
 
Events in normal diastole: 
The clinical definition of left ventricular diastole describes the time 
period between aortic and mitral valve closure, and can be subdivided 
into four interrelated events: 
a) The Isovolumic relaxation period: Which extends from aortic valve 
closure to mitral opening. Left ventricular pressure declines rapidly 
without any ventricular filling, and, by definition no change in left 
ventricular volume occurs. The duration of this period increases with age, 
but is in the range of 60-90 ms. 
b) The early or rapid filling period: Which follows mitral valve 
opening and where the ventricle fills abruptly as a consequence of the 
positive pressure difference between left atrium and left ventricle; and the 
effect of ventricular suction (demonstrated by the left ventricular pressure 
continuing to fall immediately after mitral valve opening). In young 
normal subjects at rest 75% of ventricular filling occurs during this 
period, which has a duration of approximately 200ms. (Also called as 
protodiastolic period). 
c) Diastasis: Where the atrial ventricular equalize, but filling may 
continue due to the momentum of blood during the proceeding rapid 
filling phase. The duration of this period depends on heart rate and 
almost disappear at times of tachycardia. Approximately 5% of left 
ventricular filling occur during this phase. 
d) Atrial systole: (Late rapid filling phase) Which finishes with mitral 
valve closure, accounts for about 20% of ventricular filling in young 
normal subjects, although with increasing age greater filling occurs in 
this period. This is also known as atrial kick or atrial booster. 
3.6 MYOCARDIAL SYSTOLIC DYSFUNCTION AND HEART 
FAILURE: 
The primary abnormality in non valvular heart failure is 
impairment in the left ventricular function, leading to a fall in cardiac 
output. The fall in cardiac output leads to activation of several 
neurohormonal compensatory mechanisms aimed at improving the 
mechanical environment of the heart. Activation of the sympathetic 
system, for example tries to maintain cardiac output with an increase in 
heart rate, increased myocardial contractility and peripheral 
vasoconstriction (Increased catecholamines). Activation of Renin 
angiotensin aldosterone system also results in vasoconstriction and 
increase in blood volume, with retention of salt and water. Concentration 
of vasopressin and natriuretic peptides increase. 
 
RAAS : 
Stimulation of the RAAS leads to increased concentration of renin, 
angiotension II and aldosterone. Angiotension II is a potent 
vasoconstrictor of the renal and systemic circulation where it stimulates 
release of noradrenaline from sympathetic nerve terminals which inhibits 
vagal tone and promotes the release of aldosterone. This leads to the 
retention of sodium and water. In addition, angiotension II has an 
important effects on cardiac myocytes and may contribute to the 
endothelial dysfunction that is observed in chronic heart failure.  
 
Fig(2) Renin-angiotensin-aldosterone System(RAAS) 
 
 
Sympathetic nervous system:  
The sympathetic nervous system is activated in heart failure via 
low and high pressure baroreceptors, as an early compensatory 
mechanism which provides Activation of sympathetic nervous system 
inotropic support and maintains cardiac output. In the long term, the 
ability of the myocardium to respond to chronic high concentration of 
catecholamines is attenuated by a down regulation in beta receptors. This 
may be associated with baroreceptor dysfunction and a further increase in 
sympathetic activity. 
  
 
 
 
 
 
 
 
 
 
Figure (3)Neurohumoral Response in Heart Failure 
 
 
 
 
 
Natriuretic peptide
(37)
: 
There are 3 natriuretic peptides of similar structure and these exert 
a wide range of effects on the heart, kidneys and central nervous system. 
Atrial natriuretic peptides is released from the atria in response to stretch, 
leading to natriuresis and vasodilatation. In humans, brain natriuretic 
peptide (BNP) is also released from the heart (mainly from the ventricles) 
and its actions are similar to those of ANP. C-type natriuretic peptide is 
limited to the vascular endothelium and central nervous system and has 
only limited effects on natriuresis and vasodilatation.BNP and NT Pro 
BNP values on average lower in HFnlEF as compared with HF with 
reduced EF. 
 
Vasopressin
(1)
: 
Vasopressin concentration is also increased in severe chronic heart 
failure. High concentrations of the hormone are particularly common in 
patients receiving diuretic treatment and this may contribute to the 
development of hyponatremia.  
 
Endothelin
(1)
: 
Endothelin is secreted by vascular endothelial cells,and cardiac 
myocytes and  is a potent vasoonstrictor on the renal vasculature, 
promoting the retention of sodium and water . 
3.7 MYOCARDIAL DYSFUNCTION DUE TO REMODELING, 
HIBERNATION AND STUNNING: 
After extensive myocardial infarction, cardiac contractility is 
frequently impaired and neurohormonal activation leads to regional 
eccentric and concentric hypertrophy of Non-infarcted segment with 
expansion of infarct zone. This is known as Ventricular Remodeling. 
Particular risk factors for this development of progressive 
ventricular dilatation after an MI include large infarcts, anterior 
infarctions, occlusion of artery related to infarction and hypertension. 
Myocardial dysfunction may also occur in response to stunning which 
describes delayed recovery of myocardial function despite restoration of 
coronary blood flow in the absence of irreversible damage. This is in 
contrast to hibernating myocardium which describes persistent 
myocardial dysfunction due to reduced perfusion although cardiac 
myocytes remain viable and myocardial contraction may improve with 
revascularization. 
 
Asymptomatic LV Systolic Dysfunction: 
Plasma norepinephrine concentrations increase early in the 
development of left ventricular dysfunction and plasma renin activity 
usually increases in patients receiving diuretic treatment. Norepinephrine 
concentration in asymptomatic LV dysfunction is a strong and 
independent predictor of the development of symptomatic heart failure 
and long term mortality. In severe untreated chronic heart failure, 
concentrations of renin, angiotension II, aldosterone, noradrenaline and 
ANP are all increased. Plasma concentrations of various neuroendocrine 
markers correlate with both the severity of heart failure and the long term 
prognosis. Patients with chronic heart failure and raised plasma 
noradrenaline concentrations do also have a worse prognosis.  
 
3.8 DIASTOLIC DYSFUNCTION AND HEART FAILURE: 
3.81 Definition of DD: 
Conceptually, diastole encompasses the time period during which 
the myocardium loses its ability to generate force and shorten and 
returns to an unstressed length and force. By extension, DD occurs when 
these processes are prolonged, slowed, or incomplete. The 
measurements that reflect changes in this normal function generally 
depend on the onset, rate, and extent of ventricular pressure decline and 
filling and the relationship between pressure and volume or stress and 
strain during diastole. Moreover, if diastolic function is truly normal, 
these measurements must remain normal both at rest and during the 
stress of a variable heart rate, stroke volume, end-diastolic volume, and 
blood pressure
(11)
. 
 
3.82 Mechanisms That Cause DD: 
Conceptually, the mechanisms that cause abnormalities in 
diastolic function that lead to the development of diastolic heart failure 
can be divided into factors intrinsic to the myocardium itself 
(myocardial) and factors that are extrinsic to the myocardium 
(extramyocardial; Table 2). Myocardial factors can be divided into 
structures and processes within the cardiac muscle cell (cardiomyocyte), 
within the extracellular matrix (ECM) that surrounds the cardiac muscle 
cell, and that activate the autocrine or paracrine production of 
neurohormones. Each of these mechanisms are active in the major 
pathological processes that result in DD and heart failure. Myocardial 
and extramyocardial mechanisms, cellular and extracellular 
mechanisms, and neurohumoral activation each play a role in the 
development of diastolic heart failure caused by ischemia, pressure-
overload hypertrophy, and restrictive and hypertrophic 
cardiomyopathy
(12)
 
 
TABLE NO-2 
 
Diastolic Heart Failure: Mechanisms
(12) 
 
Extramyocardial 
    Hemodynamic load: early diastolic load, afterload 
    Heterogeneity 
    Pericardium 
Myocardial 
    Cardiomyocyte 
        Calcium homeostasis 
            Calcium concentration 
            Sarcolemmal and SR calcium transport function 
            Modifying proteins (phospholamban, calmodulin, 
calsequestran) 
      Myofilaments 
            Tn-C calcium binding 
            Tn-I phosphorylation 
            Myofilament calcium sensitivity 
            /ß-myosin heavy chain ATPase ratio 
        Energetics 
            ADP/ATP ratio 
            ADP and Pi concentration 
        Cytoskeleton 
            Microtubules 
            Intermediate filaments (desmin) 
            Microfilaments (actin) 
            Endosarcomeric skeleton (titin, nebulin) 
    Extracellular matrix 
        Fibrillar collagen 
        Basement membrane proteins 
        Proteoglycans 
        MMP/TIMP 
    Neurohormonal activation 
        Renin-angiotensin-aldosterone 
        Sympathetic nervous system 
        Endothelin 
        Nitric oxide 
        Natriuretic peptides  
 
MMP indicates matrix metalloproteinase; TIMP, tissue inhibitor of 
matrix metalloproteinase. 
 
 
 
 
 
 
 
Cardiomyocyte: 
DD can be caused by mechanisms that are intrinsic to the cardiac 
muscle cells themselves. These include changes in calcium homeostasis 
caused by 
1. Abnormalities in the sarcolemmal channels responsible for short- 
and long-term    extrusion of calcium from the cytosol, such as the 
sodium calcium exchanger and the calcium pump. 
2. Abnormal sarcoplasmic reticulum calcium (SR Ca2+) reuptake 
caused by a decrease 
3. in SR Ca2+ ATPase and Changes in the phosphorylation state of 
the proteins that modify SR Ca2+ ATPase function, such as 
phospholamban, calmodulin, and calsequestrin. Changes in any of 
these processes can result in increased cytosolic diastolic calcium 
concentration, prolongation in the calcium transient, and delayed 
and slowed diastolic decline in cytosolic calcium concentration. 
These changes have been shown to occur in cardiac disease and 
cause abnormalities in both active relaxation and passive 
stiffness
(12)
. 
 
The myofilament contractile proteins consist of thick-filament 
myosin and thinfilament actin proteins. Bound to actin are a complex of 
regulatory proteins that include tropomyosin and troponin (Tn) T, C, and 
I. During relaxation, ATP hydrolysis is required for myosin detachment 
from actin, calcium dissociation from Tn-C, and active sequestration of 
calcium by the SR. Modification of any of these steps, the myofilament 
proteins involved in these steps, or the ATPase that catalyzes them can 
alter diastolic function(12).  Thus, relaxation is an energy-consuming 
process. Energetic factors necessary to maintain normal diastolic function 
include the requirement that the concentration of the products of ATP 
hydrolysis (ADP and inorganic phosphate [Pi]) must remain low and 
produce the appropriate relative ADP/ATP ratio.  DD will occur if the 
absolute concentration of ADP or Pi increases or if the relative ratio of 
ADP/ATP rises. Abnormalities in these energetics factors may be caused 
by a limited ability to recycle ADP to ATP because of a decrease in 
phosphocreatine. 
The cardiomyocyte cytoskeleton is composed of microtubules, 
intermediate filaments (desmin), microfilaments (actin), and 
endosarcomeric proteins (titin, nebulin, - actinin, myomesin, and M-
protein). Changes in some of these cytoskeletal proteins have been shown 
to alter diastolic function.
(1)
  Changes in titin isotypes have been shown to 
alter relaxation and viscoelastic stiffness. During contraction, potential 
energy is gained when titin is compressed, and during diastole, titin acts 
like viscoelastic springs, expends this stored potential energy, and 
provides a recoiling force to restore the myocardium to its resting length.  
In addition, titin extension during diastole is limited and protects the 
myocardium from being stretched too far beyond resting length. In 
experimental endstage dilated cardiomyopathy, titin isoforms and 
distribution have been shown to change in a manner that confers an 
increase in stiffness. Likewise, an increase in microtubule density and 
distribution has been shown in some forms of pressure overload to act as 
a viscous load and increase myocardial and cardiomyocyte viscoelastic 
stiffness. This change in diastolic function is reversible when 
microtubules are acutely depolymerized by chemical or physical agents. 
 
Extracellular Matrix: 
Changes in the structures within the ECM can also affect diastolic 
function. The myocardial ECM is composed of 3 important constituents: 
(1) fibrillar protein, such as collagen type I, collagen type III, and elastin; 
(2) proteoglycans; and (3) basement membrane proteins, such as collagen 
type IV, laminin, and fibronectin. It has been hypothesized that the most 
important component within the ECM that contributes to the 
development of diastolic heart failure is fibrillar collagen. The evidence 
that suggests that changes in ECM fibrillar collagen play an important 
role in the development of DD and diastolic heart failure follows 3 lines. 
First, disease processes that alter diastolic function also alter ECM 
fibrillar collagen, particularly in terms of its amount, geometry, 
distribution, degree of cross-linking, and ratio of collagen type I versus 
collagen type III. Second, treatment of these disease processes, which is 
successful in correcting diastolic function, is associated with 
normalization of fibrillar collagen. Third, experiments in which a chronic 
alteration in collagen metabolism is accomplished result in an alteration 
of diastolic function. The role played by other fibrillar proteins, the 
basement membrane proteins, and the proteoglycans remains largely 
unexplored. 
The regulatory control of collagen biosynthesis and degradation 
has at least 3 major determinants: transcriptional regulation by physical, 
neurohumoral, and growth factors; posttranslational regulation, including 
collagen cross-linking; and enzymatic degradation. Collagen synthesis is 
altered by load, including preload and afterload; neurohumoral activation, 
including the renin-angiotensin-aldosterone system (RAAS) and 
sympathetic nervous system; and growth factors. Collagen degradation is 
under the control of proteolytic enzymes, which includes a family of 
zinc-dependent enzymes, the matrix metalloproteinases (MMPs).The 
balance between synthesis and degradation results in the total collagen 
present in a given pathological state at a specific time. Changes in either 
synthesis or degradation and their regulatory processes have been shown 
to alter diastolic function and lead to the development of diastolic heart 
failure. 
 
Neurohumoral and Cardiac Endothelial Activation: 
Both acutely and chronically, neurohumoral and cardiac 
endothelial activation and/or inhibition have been shown to alter diastolic 
function. Chronic activation of the RAAS has been shown to increase 
ECM fibrillar collagen and to be associated with increased stiffness. 
Inhibition of RAAS prevents or reverses this increase in fibrillar collagen 
and generally but not consistently reduces myocardial stiffness. In 
addition, acute activation or inhibition of neurohumoral and cardiac 
endothelial systems has been shown to alter relaxation and stiffness. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure (4) Pressure-volume loops contrasting isolated diastolic heart 
failure (A) with systolic heart failure (B) and combined systolic and 
diastolic heart failure (C). A normal patient (solid line) is compared with 
a patient with heart failure before (dashed line) and after (dotted line) 
treatment. HF indicates heart failure
(11)
. 
These acute pharmacological interventions act in a time frame too 
short to alter the ECM; therefore, their effect on diastolic function must 
be caused by direct action on the cardiomyocyte to alter 1 or more 
cellular determinants of diastolic function. For example, acute treatment 
of patients with pressure overload with an ACE inhibitor, a direct NO 
donor, or an indirect endothelin-dependent NO donor caused left 
ventricular (LV) pressure decline and LV filling to be more rapid and 
complete and caused the LV pressure-versus-volume relationship to shift 
to the right, decreasing stiffness. In addition, there is a cyclical release of 
NO in the heart that is most marked subendocardially and that peaks at 
the time of relaxation and filling. These brief bursts of NO release 
provide a beat-to-beat modulation of relaxation and stiffness. 
 
3.9 ECHOCARDIOGRAPHY 
Echocardiography has come a long way since its invention by Dr. 
Edler and Hertz from Sweden in the early 1950s. Today it is recognized 
as one of the most important diagnostic techniques available in 
cardiovascular medicine. 
 
3.91 TYPE OF ECHOCARDIOGRAM 
1. M-Mode: This provides an unidimensional time motion image of 
the cardiac structures with great sensitivity. The M-mode tracing is 
also called. Ice-pick View, M-stands for motion. 
2. Two-dimensional: This provides a two dimensional image of the 
cardiac structures. It can be static or real time. 
3. Doppler echocardiography: M-Mode and two-dimensional 
echocardiography essentially create ultrasonic images of the heart 
Doppler echocardiography utilizes to record blood flow within the 
cardiovascular system. 
 
3.92.ASSESSMENT OF DIASTOLIC FUNCTION USING 
DOPPLER
(16)
: 
Doppler flow pattern in the left ventricular inflow tract just beyond 
the mitral valve superficially resembles an M-mode tracing of the 
anterior mitral leaflet. There is rapid inflow in the early diastole, 
decreased flow in the mid diastole and subsequent increase in inflow with 
atrial systole. Doppler echocardiography has been used to evaluate left 
ventricular diastolic function. M-mode technique has been used to record 
the rate of relaxation of the left ventricular cavity. 
IRT (Isovolumetric relaxation time) can be measured by two ways  
1) M-Mode Echocardiography,  
2) Similar interval may be measured by combining Doppler 
echocardiography and phonocardiogram. We use this technique to 
measure IRT. 
This phenomena has been quantitated in several ways. The simple 
technique is to take a ratio of the peak velocity with early filling or E 
point and the peak velocity with atrial filling or A point. Normally the 
velocity at the E point is significantly higher than that at the A point. 
With reduced early left ventricular filling this ratio is reversed(Grade-1 
DD). With restrictive ventricular filling the diastolic velocities may again 
reverse with a tall E-wave and reduced A-wave. This is called as 
Pseudonormalisation(Grade-2 DD).  Pseudonormalisation is also seen in 
patient with more severe impairment of diastolic performance than the 
pattern of delayed relaxation. Restrictive filling (Grade-3 DD) which is 
reversible to Grade-2 with valsalva manoeuvre. Grade-4 DD which is 
restrictive filling and irreversible to Grade-2 with valsalva manoeuvre
(15)
. 
Transmitral inflow (E/A; E wave deceleration): The E wave occurs 
related to LV `suction' and LA pressure - the E wave acceleration will be 
higher with high LA pressure, and lowered with impaired LV relaxation. 
Deceleration of inflow of the E wave is measured by deceleration time 
(DT), which shortens with decreasing LV compliance. DT is rather 
complex, as higher LA pressures shorten it. A normal DT is about 
200±32ms; values over 240ms indicate impaired relaxation, and under 
150ms suggest restriction.  
 
 
 
 
 
 
 
 Fig (5): Recordings are obtained from a normal individual and 
patients with diastolic dysfunction. A) Normal individual - 70 years old 
(6.581.360); B) Abnormal relaxation in a 55- year -old man with LVH 
(on hemodialysis); C) a 44 -year old man with LV hypertrophy and D) a 
41-year -old man with end-stage heart failure
(16)
. 
Pulmonary venous inflow (atrial flow reversal): Pulmonary vein 
Doppler is easily imaged using TOE, but may even be performed on TTE 
using a foreshortened apical cross-section. The normal pattern is to see a 
systolic (S) wave, a diastolic (D) wave, with perhaps some retrograde 
flow during atrial contraction. The last wave is sometimes called the A R 
wave - it normally has an amplitude of under 25cm/s, and a shorter 
duration than the transmitral A wave. Velocity and duration of A R 
increase with worsening diastolic dysfunction.  
 
 
 
 
 
 
Fig (6): Pulmonary Venous flow in Restrictive filling 
 
Tissue Doppler imaging (TDI): LVD can be more soundly established 
by Tissue Doppler imaging (TDI) and invasively by Cardiac 
Catheterization. TDI yield E/E’ ratio Greater than 15 then additional 
echovariables like Doppler flow profile of mitral valve or pulmonary 
veins and measurement of LV mass index or Left atrial volume index 
can be assessed. If Cardiac Catheterization shows LV diastolic pressure 
Greater than 16mmHg or mean Pulmonary capillary wedge pressure 
Greater than 12mmHg. Echo Doppler techniques using LV filling 
pressure and TDI of mitral annulus help in identifying and classifying 
degree of LV diastolic dysfunction
(13), (40)
. 
 
3.10 TREATMENT OF HEART FAILURE WITH PRESERVED 
EJECTION FRACTION: 
 
General Approach
(12)
: 
 The guidelines for the management of diastolic heart failure are 
based on clinical investigations in relatively small groups of patients, 
clinical experience, and concepts based on pathophysiological 
mechanisms. 
Treatment of diastolic heart failure can be framed in 3 steps.  
       First, treatment should target symptom reduction, principally by 
decreasing pulmonary venous pressure at rest and during exertion. Both 
nonpharmacological and pharmacological approaches proposed but not 
proven to be effective in targeting symptoms are listed in Table 3. 
      Second, treatment should target the pathological disease that caused 
the diastolic heart failure. For example, coronary artery disease, 
hypertensive heart disease, and aortic stenosis provide relatively specific 
therapeutic targets, such as lowering of blood pressure, induction of 
hypertrophy regression, performance of aortic valve replacement, and 
treatment of ischemia by increasing myocardial blood flow and reducing 
myocardial oxygen demand. 
      Third, treatment should target the underlying mechanisms that are 
altered by the disease processes. 
 
Fig (7): Diagnosis of Heart Failure with Normal Ejection Fraction
(12), (36) 
TABLE NO-3 
Diastolic Heart Failure: Treatment
(12)
  
 
Symptom-targeted treatment 
     Decrease pulmonary venous pressure 
     Reduce LV volume 
     Maintain atrial contraction 
     Prevent tachycardia 
     Improve exercise tolerance 
     Use positive inotropic agents with caution 
Nonpharmacological treatment 
   Restrict sodium to prevent volume overload 
   Restrict fluid to prevent volume overload 
   Perform moderate aerobic exercise to improve cardiovascular    
   conditioning, decrease heart rate, and maintain skeletal  
   muscle function 
Pharmacological treatment 
   Diuretics, including loop diuretics, thiazides, spironolactone 
   Long-acting nitrates 
   ß-Adrenergic blockers 
   Calcium channel blockers 
   Renin-angiotensin-aldosterone antagonists, including ACE inhibitors,      
   angiotensin II receptor blockers, and aldosterone antagonists 
Disease-targeted treatment 
   Prevent/treat myocardial ischemia 
   Prevent/regress ventricular hypertrophy 
Mechanism-targeted treatment 
   Modify myocardial and extramyocardial mechanisms 
   Modify intracellular and extracellular mechanisms 
3.101 SYMPTOM-TARGETED TREATMENT: 
Decrease Diastolic Pressure: 
The initial step in treating patients presenting with diastolic heart 
failure is to reduce pulmonary congestion by decreasing LV volume, 
maintaining synchronous atrial contraction, and increasing the duration 
of diastole by reducing heart rate LV diastolic pressures can be decreased 
by reducing total blood volume (eg, through fluid and sodium restriction 
or use of diuretics), decreasing central blood volume (nitrates), and 
blunting neurohumoral activation. Treatment with diuretics and nitrates 
should be initiated at low doses to avoid hypotension and fatigue. 
Hypotension can be a significant problem, because these patients have a 
very steep diastolic pressurevolume curve such that a small change in 
diastolic volume causes a large change in pressure and cardiac output. 
One mechanism that causes fluid retention and an increase in 
central and systemic volume is activation of these neurohumoral systems. 
Therefore, treatment for diastolic heart failure might include agents such 
as ACE inhibitors, AT1 receptor antagonists, and aldosterone 
antagonists. In addition to promoting fluid retention, neurohumoral 
activation can have direct effects on cellular and extracellular 
mechanisms that contribute to the development of diastolic heart failure. 
Modulation of neurohumoral activation may also affect fibroblast 
activity, interstitial fibrosis, intracellular calcium handling, and 
myocardial stiffness. 
Tachycardia is poorly tolerated in patients with diastolic heart 
failure for several reasons.  
First, rapid heart rates cause an increase in myocardial oxygen 
demand and a decrease in coronary perfusion time, which can promote 
ischemic diastolic dysfunction even in the absence of epicardial coronary 
disease, especially in patients with LV hypertrophy.  
Second, a shortened diastole may cause incomplete relaxation 
between beats, resulting in an increase in diastolic pressure relative to 
volume.  
Third, hearts with diastolic dysfunction exhibit a flat or even 
negative relaxation velocity–versus– heart rate relationship, so that as 
heart rate increases, relaxation rate does not increase or may even 
decrease, which can then cause diastolic pressures to increase β-Blockers 
and some calcium channel blockers can thus be used to prevent excessive 
tachycardia and produce a relative bradycardia. Although the optimal 
heart rate must be individualized, an initial goal might be a resting heart 
rate of  60 to 70 bpm with a blunted exercise-induced increase in heart 
rate. 
Improve Exercise Tolerance: 
Patients with diastolic heart failure have a marked limitation in 
exercise tolerance. There are a number of mechanisms responsible for 
this limitation. In patients with diastolic heart failure, the ability to use 
the Frank-Starling mechanism is limited despite the increased filling 
pressures because increased diastolic stiffness prevents the increase in 
LV end diastolic volume that normally accompanies exercise. The 
abnormal relaxation velocity–versus–heart rate relationship that exists in 
patients with diastolic heart failure prevents augmentation of relaxation 
velocity as heart rate increases during exercise. As a result, during 
exercise, diastolic pressure increases, the stroke volume fails to rise, and 
patients experience dyspnea and fatigue. In patients with diastolic heart 
failure, there is frequently an exaggerated rise in blood pressure in 
response to exercise that increases LV load and in turn further impairs 
myocardial relaxation and filling. β-Blockers, calcium channel blockers, 
and AT1 antagonists may have a salutary effect on symptoms and 
exercise capacity in many patients with diastolic heart failure. 
Use Positive Inotropic Drugs With Caution: Positive Inotropic agents 
are generally not used in the treatment of patients with isolated diastolic 
heart failure because the ejection fraction is preserved, and there appears 
to be little potential benefit. Moreover, such drugs have the potential to 
worsen the pathophysiological processes that cause diastolic heart failure. 
In contrast to long-term use, positive inotropic drugs may be beneficial in 
the short-term treatment of pulmonary edema associated with diastolic 
heart failure because they enhance SR function, promote more rapid and 
complete relaxation, increase splanchnic blood flow, increase venous 
capacitance, and facilitate diuresis. However, even short-term treatment 
with these agents may adversely affect energetics, induce ischemia, raise 
heart rate, and induce arrhythmias. Therefore, these agents should be 
used with caution, if they are used at all. Results of the Digitalis 
Investigation Group trial53 suggested that patients with heart failure and 
a normal ejection fraction may have fewer symptoms and fewer 
hospitalizations if they are treated with digitalis.  
 
Differences between Pharmacological Treatment of Systolic and 
Diastolic Heart Failure:  
With a number of notable exceptions, many of the drugs used to 
treat diastolic heart failure are in fact the same as those used to treat 
systolic heart failure. However, the rationale for their use, the 
pathophysiological process that is being altered by the drug, and the 
dosing regimen may be entirely different depending on whether the 
patient has systolic or diastolic heart failure. For example, β-blockers are 
now recommended for the treatment of both systolic and diastolic heart 
failure. In diastolic heart failure, however, β-blockers are used to 
decrease heart rate, increase the duration of diastole, and modify the 
hemodynamic response to exercise. In systolic heart failure, β-blockers 
are used chronically to increase inotropic state and modify LV 
remodeling. In systolic heart failure, β-blockers must be titrated slowly 
and carefully over an extended time period. This is generally not 
necessary in diastolic heart failure. Diuretics are used in the treatment of 
both systolic and diastolic heart failure. However, the doses of diuretics 
used to treat diastolic heart failure are generally smaller than the doses 
used in systolic heart failure. Some drugs are used only to treat either 
systolic or diastolic heart failure but not both. For example, calcium 
channel blockers such as diltiazem, nifedipine, and verapamil have no 
place in the treatment of systolic heart failure. By contrast, each of these 
has been proposed as being useful in the treatment of diastolic heart 
failure. 
 
Mechanism-Targeted Treatment (Future Directions): 
An ideal therapeutic agent should target the underlying 
mechanisms that cause diastolic heart failure. Therefore, a therapeutic 
agent might improve calcium ho-meostasis and energetics, blunt 
neurohumoral activation, or prevent and regress fibrosis. Fortunately, 
some pharmaceutical agents that fit these design characteristics are 
already in existence, and many more are under development.. Diastolic 
heart failure is now recognized as an important problem, guidelines for 
diagnosis have been developed .Three trials are now under way .Two of 
these trials target neurohumoral activation in the RAAS by inhibiting the 
angiotensin II receptor (Candesartan cilexetil in Heart failure Assessment 
of Reduction in Mortality and morbidity [CHARM] and Wake Forest). 
The third study targets intracellular calcium homeostasis using an agent 
that is proposed to improve SR calcium reuptake (MCC-135). With these 
3 studies, and others that are currently under development, an effective 
treatment for diastolic heart failure will be more completely defined. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods      
MATERIAL AND METHODS 
 
Study involving 103 Patients of Heart Failure admitted in General 
Medical Ward of Coimbatore Medical College Hospital (CMCH) over 
the period of one year from September 2009 to September 2010. 
All the patients were evaluated with 
1. Thorough Histroy 
2. Complete Physical Examination 
3. Chest X-Ray 
4. ECG 
5. Complete Blood Count 
6. Renal Function Test 
7. Fasting Blood Sugar 
8. Lipid Profile 
 
After initial evaluation all patients were routinely underwent M-mode 
and Two Dimensional Echocardiography. 
 
Study Design: Observational Study 
Statistical Method: Continuous data were expressed as mean±SD (i.e. 
Age, SBP, DBP, LVEDD, LVESD and EF), age distribution between 
males and females compared with X
2
 Test (Chi Square Test). P=0.05 Just 
Significant (JS) P<0.05 Significant(S), P<0.001 – Highly Significant 
(HS). 
Collaborating Department: Cardiology 
Inclusion Criteria: All patients with Signs and Symptoms of Heart 
Failure who fulfills the Framingham Criteria. 
Exclusion Criteria:  
1. Patients with Age Less than 12 years. 
2. Valvular Heart Disease 
3. Congenital Heart Disease 
4. Established Renal Failure 
5. Pregnant Women 
6. Patients with CorPulmonale. 
 
  
 
 
 
 
 
 
 
 
 
Observation and Analysis                  
OBSERVATIONS AND DATA ANALYSIS 
 
103 Patients of Heart failure were analyzed. Among them 43(42%) 
were Heart Failure with Preserved Ejection Fraction (EF ≥ 50%) and 
60(58%) were Heart Failure with Reduced Ejection Fraction (EF < 50%). 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE NO- 4 
AGE AND SEX DISTRIBUTION 
 
EF < 50 ( n=60) EF ≥ 50 ( n=43) 
AGE( in 
yrs) 
Male Female Male Female 
25-35 1 0 0 0 
36-45 9 5 1 2 
46-55 13 5 8 4 
56-65 13 9 8 5 
66 & above 3 2 4 11 
Total 39 21 21 22 
Age(in Yrs) 51.97±10.25 54±10.73 57.43±9.37 62.86±12.17 
Age(in Yrs) 52.68±10.38 60.21±11.11 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
X
2 
TEST FEMALE MALE Total 
Ratio (i.e 
FEMALE) 
No of cases with  EF ≥ 
50%(n=43) 22 21 43 51.1627907 
No of cases with  EF < 
50%(n=60) 21 39 60 35.00 
Total 43 60 103 
The observed X
2 
value was 2.69 which was much lower than 95% 
CI value which was 3.84. Female patients were more significant in 
HFPEF (F.M Ratio 51) is than HFrEF (F.M. Ratio 35) 
 Women with the age of 65 yrs and above group (25%) were 
mostly affected with HFPEF. 
 Mean age of HFPEF was 53±10yrs whereas 62±11yrs in HFrEF. 
TABLE NO-5 
SYMPTOMS PROFILE 
 
HF WITH 
PRESERVED EF 
(n=43) 
P Value Significance 
Breathlessness 40 P <0.001 Highly Significant 
Orthopnea 21 P <0.05 Significant 
H/O Oedema 13 P=0.05 Just Significant 
Palpitation 24 P <0.001 Highly Significant 
Chest Pain 14 P=0.05 Just Significant 
 
HF WITH 
REDUCED EF 
(n=60) 
P Value Significance 
Breathlessness 56 P<0.001 Highly Significant 
Orthopnea 41 P<0.001 Highly Significant 
H/O Oedema 46 P<0.001 Highly Significant 
Palpitation 28 P<0.001 Highly Significant 
Chest Pain 31 P<0.001 Highly Significant 
 
Exertional breathlessness was the most common presenting 
Symptom (93%) in both types of HF. Palpitaion and Orthopnea were 
next most common presenting symptoms in HF. Edema legs in HFPEF 
was 30% whereas 77% in HFrEF. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE NO.-6 
PHYSICAL SIGNS 
 
PRESERVED EF  
(n=43) 
P Value Significance 
Pedal Edema 13 P=0.05 Just Significant 
JVP 34 P<0.001 Highly Significant 
LV-S3 0 P>0.05 Not Significant 
Murmur 0 P>0.05 Not Significant 
Rales 43 P<0.001 Highly Significant 
Hepatomegaly 6 P>0.05 Not Significant 
PULSE AF 4 P>0.05 Not Significant 
PULSE ST 26 P<0.001 Highly Significant 
PULSE VPC 8 P>0.05 Not Significant 
PULSE 
NORMAL 
5 P>0.05 Not Significant 
SBP 148.33±15.29 
  
DBP 90.09±25.29 
  
 
REDUCED EF 
(n=60) 
P Value Significance 
Pedal Edema 46 P<0.001 Highly Significant 
JVP 50 P<0.001 Highly Significant 
LV-S3 15 P<0.05 Significant 
Murmur 13 P<0.05 Significant 
Rales 60 P<0.001 Highly Significant 
Hepatomegaly 25 p<0.001 Highly Significant 
PULSE AF 4 P>0.05 Not Significant 
PULSE ST 31 P<0.001 Highly Significant 
PULSE VPC 6 P>0.05 Not Significant 
PULSE 
NORMAL 
19 P<0.001 Highly Significant 
SBP 120.24±`9.66 
  
DBP 80.67±15.52 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Rales in the lung fields was present in 100% of HF patients and 
Elevated JVP was the 2
nd
 most common sign.  
 Mean SBP was 148±15 mmHg in HFPEF whereas 120±10 mmHg 
in HFrEF. 
 Mean DBP was 90±25 mmHg in HFPEF whereas 80±15 mmHg 
in HFrEF. 
   
 
 
 
 
 
 
TABLE NO-7 
MAJOR RISK FACTORS 
 
PRESERVED EF  
(n=43) 
P Value Significance 
SHT 33 P<0.001 Highly Significant 
DM 14 P=0.05 Just Significant 
CAD 9 P>0.05 Not Significant 
Alcoholism 4 P>0.05 Not Significant 
Smoking 9 P>0.05 Not Significant 
 
REDUCED EF 
(n=60) 
P Value Significance 
SHT 29 P<0.001 Highly Significant 
DM 24 P<0.001 Highly Significant 
CAD 36 P<0.001 Highly Significant 
Alcoholism 23 P<0.001 Highly Significant 
Smoking 32 P<0.001 Highly Significant 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
SHT was the most common risk factor in HFPEF whereas CAD in 
HFrEF.DM was significant risk factor in both types of HF. Alcoholism 
and smoking were significant in HFrEF than in HFPEF. 
 
TABLE NO-8 
ECG FEATURES 
Features HF WITH 
PRESERVED 
EF(n=43) 
P Value Significance 
LVH 17 P<0.05 Significant 
LAE 27 P<0.001 Highly Significant 
AF 4 P>0.05 Not Significant 
LBBB 5 P>0.05 Not Significant 
RBBB 1 P>0.05 Not Significant 
IHD 21 P<0.05 Significant 
Features 
HF WITH REDUCED 
EF(n=60) 
P Value Significance 
LVH 19 P<0.05 Significant 
LAE 35 P<0.001 Highly Significant 
AF 4 P>0.05 Not Significant 
LBBB 5 P>0.05 Not Significant 
RBBB 2 P>0.05 Not Significant 
IHD 54 P<0.001 Highly Significant 
 
 
 
 
  
 
 
 
 
 
 
 
LAE was the significant manifestation in ECG (63%) in HFPEF, 
58% in HFrEF. Evidence of IHD was 90% in HFrEF, 48% in HFPEF.  
3
rd
 common manifestation was LVH.AF (9%) in HFPEF (not 
significant), 7% in HFrEF (not significant). 
 
TABLE NO-9 
CHEST X-RAY FINDINGS 
Findings HF WITH 
PRESERVED 
EF(n=43) 
P Value Significance 
Cardiomegaly 14 P=0.05 Just Significant 
Pulm.V.HT 31 P<0.0001 More Significant 
Pl.Eff 0 P>0.05 Not Significant 
Findings 
HF WITH 
REDUCED 
EF(n=60) 
P Value Significance 
Cardiomegaly 40 P<0.001 Highly Significant 
Pulm.V.HT 52 P<0.001 Highly Significant 
Pl.Eff 12 P=0.05 Just Significant 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Pulmonary venus HT was the Highly Significant finding in both types of 
HF. Cardiomegaly and pleural effusion were significant in HFrEF than 
HFPEF.  
TABLE NO-10 
ECHOCARDIOGRAPHIC FEATURES 
 
  EF ≥ 50% EF < 50 
LVEDD 43.67±6.11 56.52±7.45 
LVESD 29.93±4.48 45.88±7.11 
LVEF 61.4%±7.8% 32.85%±8.14% 
 
HF WITH PRESERVED EF 
( n=43) 
P Value Significance 
Hypokinesia 16 P<0.05 Significant 
DD 37 P<0.001 Highly Significant 
 SD 10 P>0.05 Not Significant 
Normal (without 
SD,DD) 
6 P>0.05 Not Significant 
HF WITH REDUCED EF (n=60) P Value Significance 
Hypokinesia 56 P<0.001 Highly Significant 
DD 6 P>0.05 Not Significant 
SD 60 P<0.001 Highly Significant 
Normal (without 
SD,DD) 
0 P>0.05 Not Significant 
 
 
 
  
 
 
 
 
 
Mean EF in HFPEF was 61%±8% 
Mean EF in HFrEF  was 33%±8% 
Mean LVEDD was 44±6 mm in HFPEF. 
Mean LVEDD was 56.5±7 mm in HFrEF. 
Observed E/A ratio were reduced to below one in HFPEF(Mean is 0.83). 
 Hypokinesia of Left Ventricle was 93% in HFrEF whereas 37% in 
HFPEF. DD was present in 86% of HFPEF, 10% in HFrEF. SD was 
present in all patients of HFrEF, 23% in HFPEF. 14% HF patients had no 
evidence of DD or SD in EF ≥ 50%. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Discussion          
DISCUSSION 
 
 An estimated half of all patients with HF have preserved ejection 
fraction. The risk factors, clinical features, pathophysiology and course of 
the illness have extensively been studied recently. 
 
 In the present series 103 patients of heart failure fulfilling 
Framingham criteria who were admitted in General Medical Ward in 
Coimbatore Medical College Hospital, Coimbatore-18, during the period 
between September 2009 to September 2010 were studied.  
 
 Most have demonstrated minimal difference between clinical 
symptoms, signs, radiographic findings and have documented that none 
of the clinical features can be used to distinguish patients with HFPEF 
reliably from those with HFrEF. Assessment of EF with cardiac imaging 
is needed to distinguish HFPEF with HFrEF. 
 
 Present study can be seen as an assessment of the clinical course of 
HF with preserved EF as compared with that of HF with reduced EF from 
the same point in the evaluation of the disease. 
 
 In the present study, 42% of HF patients had an EF≥50%. Women 
>65yrs of age were more affected. Subtle differences were observed on 
physical examination. AF did not show significance in HFPEF (9%) as 
well as in HFrEF (7%) whereas Theophilus E Owan et al.
(34) 
 studies 
showed that it was significant in HFPEF(41%). SHT, CAD and DM were 
the most significant risk factors in both types of heart failure. Smoking 
and alcoholism were not significant in HFPEF, but significant in HFrEF, 
whereas Vasan et al
(5) 
 studies concluded that no significant difference 
between the two types of  heart failure. 
 
 Vasan et al
(5) 
 studies showed mean SBP was 143±24 mmHg and 
DBP was 73±13mmHg in HFPEF whereas present study showed mean 
SBP was148±15mmHg and mean DBP was 90±25mmHg in patients with 
HFPEF. Patients with HFrEF had mean SBP 120±10mmHg, mean DBP 
80±15mHg. 
 
 ECG evidence of IHD was 48% in patients with HFPEF, 90% in 
patients with HFrEF. Evidence of LAE was highly significant in both 
types of Heart Failure. AF,RBBB, and LBBB were not significant in both 
types of Heart Failure. 
 
 Pulmonary venus hypertension (72%) was present in CXR of 
patients with HFPEF as compared to 87% in HFrEF. Cardiomegaly and 
pleural effusion were highly significant in HFrEF. 
 
 In Echocardiogram mean LVEDD is 44±6 mm in HFPEF and 
mean LVEDD is 56.5±7 mm in HFrEF. Observed E/A ratio were reduced 
to below one in HFPEF(mean is 0.83). 
 
 Micheal R Zile et al
(4)
. studied patients with HFNEF with 
Echocardiography to assess the diastolic function by the following 
parameters mainly  
 
1. Left ventricular dimension. 
2. Left ventricular wall thickness. 
3. Transmitral flow velocities (E/A ratio). 
4. Wall motion abnormalities. 
 
Patients in present study were also evaluated with the above 
parameters and cardiac catheterization was not performed as facilities 
were inadequate. 
 
 
  
 
 
 
Conclusion           
CONCLUSION 
 
1. 103 Patients of Heart failure were analyzed. Among them 42% of 
patients had EF ≥ 50% and 58% patients had EF < 50%. 
2. Mean age of patients in HFPEF was 57± 9 for males, 62.8 ± 12 for 
females. Mean age of patients in HFrEF was 52 ± 10 for males,           
54 ± 10 for females. 
3. Women with the age of 65 yrs and above (25%) were mostly 
affected with HFPEF. 
4. Exertional Breathlessness was the most common presenting 
symptom (93%) in both types of HF. Rales in the lung fields was 
present in 100% of patients with HF. Elevated JVP was the 2
nd
 
most common sign in both types of HF. 
5. Mean SBP and DBP was higher in patients with HFPEF than in 
patients with HFrEF. 
6. SHT was the most common risk factor in HFPEF (48%). CAD was 
the most common risk factor (25%) in HFrEF. DM was significant 
in both types HF. Alcoholism and smoking were significant in 
HFrEF than in HFPEF.  
7. LAE was the significant manifestation in ECG, 63% in HFPEF and 
58% in HFrEF. Evidence of IHD was 90% in HFrEF and 48% in 
HFPEF. 3
rd
 common manifestation was LVH (significant) in both 
types of HF. AF was 9% in HFPEF (not significant) and 7% in 
HFrEF (not significant). 
8.  Pulmonary venus hypertension was highly significant finding in 
both types of HF. Cardiomegaly and pleural effusion were 
significant in HFrEF than in HFPEF.  
9. SHT was the most common risk factor in HFPEF whereas CAD in 
HFrEF. 
10. DM was the significant risk factor in both types of HF. Alcoholism 
and smoking were significant in HFrEF than in HFPEF. 
11. Observed E/A ratio were reduced to below one in HFPEF (Mean 
was 0.83). 
12. About 10% of  HF patients had no evidence of DD or SD. Those 
patients  yet to be evaluated with cardiac catheterization and other 
advanced techniques. 
 
Future Direction: 
An ideal therapeutic agent should target the underlying 
mechanisms that cause diastolic heart failure. Diastolic heart failure is 
now recognized as an important problem, guidelines for diagnosis have 
been developed. Three trials are now under way. Two of these trials 
target neurohumoral activation. The third study targets intracellular 
calcium homeostasis. 
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 Annexures 
 
 




 LIST OF ABBREVIATION 
 
HFNEF, 
HFnlEF 
Heart Failure with Normal Ejection Fraction 
HFPEF Heart Failure with Preserved Ejection Fraction 
HF Heart Failure 
AF Atrial Fibrillation 
AGE Advanced Glycation End product 
ASD Atrial Septal Defect 
BNP Brain Natriuretic Peptide 
bpm beats per minute 
CAD Coronary Atery Disease 
CAHD Coronary Atery Heart Disease 
CNS Central Nervous System 
CVP Central Venus Pressure 
CVS Cardio Vascular System 
CXR Chest X-Ray 
DBP Diastolic Blood Pressure 
DD Diastolic Dysfunction 
DM Diabetes Mellitus 
ECG Electrocardiogram 
EDV End Diastolic Volume 
EF Ejection Fraction 
ESV End Systolic Volume 
HFrEF Heart Failure with Reduced Ejection Fraction 
HOCM Hypertrophic Obstructive Cardiomyopathy 
HT Hypertension 
IHD Ischemic Heart Disease 
JVP Jugular Venus Pulse 
LAE Left Atrial Enlargement 
LBBB Left Bundle Branch Block 
LV Left Ventricle 
LVEDD Left ventricular End Diastolic diameter 
LVESD Left ventricular End Systolic diameter 
LVH Left Ventricle hypertrophy 
NT-proBNP  N-terminal–pro-BNP 
RBBB Right Bundle Branch Block 
RS Respiratory System 
RV Rgith Ventricle 
SBP Systolic Blood Pressure 
SD Systolic Dysfunction 
SHT Systemic Hypertension 
SV Stroke Volume 
VO2  oxygen uptake 
BP Blood Pressure 
 
